Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

P Dreger, M Michallet, P Bosman, S Dietrich… - Bone marrow …, 2019 - nature.com
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic
hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible …
被引用次数：73 相关文章

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

P Dreger, M Michallet, P Bosman… - Bone marrow …, 2019 - pubmed.ncbi.nlm.nih.gov
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic
hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible …

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

D Peter, M Mauricette, B Paul, D Sascha… - Bone marrow …, 2019 - croris.hr
Sažetak The aim of this retrospective study was to investigate the safety and efficacy of
allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib …

[引用][C] Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the …

P Dreger, M Michallet, P Bosman, S Dietrich, M Sobh… - 2019 - oparu.uni-ulm.de

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

P Dreger, P Bosman, M van Gelder, N Kröger… - Bone Marrow …, 2019 - elibrary.ru
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic
lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and …

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

P Dreger, M Michallet, P Bosman… - Bone Marrow …, 2019 - research.regionh.dk
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic
hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible …

[引用][C] Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the …

P Dreger, M Michallet, P Bosman, S Dietrich, M Sobh… - 2019 - repository.ubn.ru.nl
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic
lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies …

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

P Dreger, M Michallet, P Bosman, S Dietrich… - Bone Marrow …, 2019 - go.gale.com
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic
hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible …

[引用][C] Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the …

P Dreger, J Finke, J Schetelig - Bone marrow transplantation, 2019 - freidok.uni-freiburg.de
FreiDok plus - Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in
patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT …

[引用][C] Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the …

P Dreger, M Michallet, P Bosman, S Dietrich… - BONE MARROW …, 2019 - iris.unibs.it